Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 672 • 2018 ACR/ARHP Annual Meeting
Activation of NLRP3 Inflammasomes in Peripheral Blood Mononuclear Cells of Patients with Ankylosing Spondylitis
Seong-Kyu Kim¹ and Jung-Yoon Choe², ¹Rheumatology, Daegu Catholic University School of Medicine, Daegu, Korea, Republic of (South), ²Department of Internal Medicine, Catholic university of Daegu School of Medicine, Daegu, Korea, Republic of (South)
Background/Purpose: NLRP3 inflammasome is a molecular platform triggering activation of inflammatory cytokines including interleukin-1b (IL-1b). This study aimed to assess the expression of NLRP3 inflammasome…
Abstract Number: 1384 • 2018 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Patients with Ankylosing Spondylitis in the United States
W. Benjamin Nowell¹, Regan Reynolds¹, Kelly Gavigan¹, Shilpa Venkatachalam¹, Marie de la Cruz², Emuella Flood², Ethan Schwartz², Beverly Romero², Yujin Park³ and Alexis Ogdie⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²ICON, Gaithersburg, MD, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Ankylosing spondylitis (AS) is a chronic, systemic, inflammatory disease that affects primarily the sacroiliac joints and spine and can cause irreversible damage. Measuring disease…
Abstract Number: 1864 • 2018 ACR/ARHP Annual Meeting
Ixekizumab Significantly Improves Signs, Symptoms, and Spinal Inflammation of Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16-Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial
Désirée van der Heijde¹, James Cheng-Chung Wei², Maxime Dougados³, Philip J. Mease⁴, Atul A. Deodhar⁵, Walter P. Maksymowych⁶, Filip van Den Bosch⁷, Joachim Sieper⁸, Tetsuya Tomita⁹, Robert B.M. Landewé¹⁰, Lotus Mallbris¹¹, Fangyi Zhao¹¹, David Adams¹¹, Beth Pangallo¹¹ and Hilde Carlier¹¹, ¹Leiden University Medical Centre, Leiden, Netherlands, ²Allergy/Immunology/Rheumatology, Chung Shan Med Univ Hospital, Taichung, Taiwan, ³Rheumatology Department, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France, Paris, France, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Oregon Health & Science U, Portland, OR, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁸Charité University Hospital, Berlin, Germany, ⁹Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan, ¹⁰Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, ¹¹Eli Lilly and Company, Indianapolis, IN
Background/Purpose: COAST-V (NCT02696785) is the first phase 3 study of ixekizumab (IXE), a high-affinity anti-IL-17A monoclonal antibody, in patients (pts) with active radiographic axial SpA…
Abstract Number: 673 • 2018 ACR/ARHP Annual Meeting
Chronic Back Pain (CBP) in First Degree Relatives (FDRs) of Patient with Ankylosing Spondylitis (AS): Comparison with the US Population, HLA-B27 Frequency and Persistence of Symptoms over Time
John D. Reveille¹, MinJae Lee², Laura A. Diekman³, Michael Ward⁴, Lianne S. Gensler⁵, Amirali Tahanan², Mohammad H. Rahbar⁶ and Michael Weisman⁷, ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ³Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ⁴National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ⁵University of California San Francisco, San Francisco, CA, ⁶Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ⁷Harbor UCLA Medical Center, Los Angeles, CA
Background/Purpose: We examined first degree relatives (FDRs) of patients with ankylosing spondylitis (AS) patients with chronic inflammatory back pain (CIBP), non-inflammatory CBP (NICBP) and no…
Abstract Number: 1386 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Work Productivity and Activity As Well As Quality of Life in Patients with Rheumatoid Arthritis (RA), Psoriasis Arthritis (PsA) and Axial Spondyloarthritis (axSpA): Interim Results from a Non-Interventional Study in Austria (Go Active)
Christian Dejaco¹, Thomas Mueller², Omid Zamani, MD³, Ulrike Kurtz, MD⁴, Stefan Egger, MD⁵, Johannes Resch Passini, MD⁶, Anna Totzauer, MD⁷, Wolfgang Eisterer⁸, Babak Yazdani-Biuki, MD, Univ.Doc.⁹, Thomas Schwingenschloegl, MD¹⁰, Peter Peichl, MD. Univ.Doc. Msc¹¹, Angelika Kraus¹², Gerhard Naerr, PhD¹³ and Verena Rickert, MD. MBA¹⁴, ¹Rheumatology and Immunology, Medical University Graz, Graz, Austria, ²Private Office Dr. Thomas Mueller, Graz, Austria, ³Rheuma Zentrum Favoriten, Vienna, Austria, ⁴Rheuma Praxis Dr. Kurtz, Gleisdorf, Austria, ⁵Ordination Gesundheitsquadrat, Vienna, Austria, ⁶Rheumatology Department, Rheuma-Zentrum Wien-Oberlaa GmbH, Vienna, Austria, ⁷Private Office Dr. Anna Totzauer, Gmuend, Austria, ⁸Department of Hematology and Internal Oncology, KLINIKUM- KLAGENFURT am WÖRTHERSEE, Klagenfurt, Austria, ⁹Dr. Schrenk & Dr. Yazdani-Biuki OG - Gruppenpraxis, Fuerstenfeld, Austria, ¹⁰Private Office Dr. Thomas Schwingenschloegl, Wiener Neudorf, Austria, ¹¹Private Office Prim. Univ. Doz. Dr. Peter Peichl, MSc, Vienna, Austria, ¹²Private Office, Private Office Angelika Kraus, Melk, Austria, ¹³Medical Affairs, Merck Sharp & Dohme GmbH, Vienna, Austria, ¹⁴Medical Affairs, Merck Sharp&Dohme GmbH, Vienna, Austria
Background/Purpose: Golimumab has shown clinical efficacy and tolerability within its clinical trial program. No systematic outcome data regarding patient‐reported outcomes and health economic parameters reflecting…
Abstract Number: 1869 • 2018 ACR/ARHP Annual Meeting
Sustained Improvements in Signs and Symptoms of Active Ankylosing Spondylitis and Reassuring Safety with Secukinumab 300mg: 3-Year Results from a Phase 3 Study
Alan J. Kivitz¹, Karel Pavelka², Eva Dokoupilova³, Ricardo Blanco⁴, Marco Maradiaga⁵, Hasan Tahir⁶, Yi Wang⁷, Brian Porter⁸, Anna Stefanska⁹, Susanne Rohrer¹⁰ and Hanno Richards¹⁰, ¹Altoona Center for Clinical Research, Duncansville, PA, ²1st Faculty of Medicine, Charles University, Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, ³University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, MEDICAL PLUS s.r.o.,, Uherske Hradiste, Czech Republic, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, ⁶Rheumatology, Barts Health NHS Trust, London, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁹Novartis Ireland Limited, Dublin, Ireland, ¹⁰Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) over 2 years in the MEASURE 3 study, which…
Abstract Number: 3L • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Low Radiographic Progression and Sustained Efficacy through 4 Years in Patients with Active Ankylosing Spondylitis
Jürgen Braun¹, Xenofon Baraliakos¹, Atul A. Deodhar², Denis Poddubnyy³, Paul Emery⁴, Evie Maria Delicha⁵, Zsolt Talloczy⁶ and Brian Porter⁶, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, ²Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Leeds Musculoskeletal Biomedical Research Unit/Institute Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ

Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, reported improved signs and symptoms of ankylosing spondylitis (AS) in the MEASURE 1 trial.1 Here, we report…
Abstract Number: 997 • 2017 ACR/ARHP Annual Meeting
Incidence and Clinical Characteristics of Active Tuberculosis in a Cohort of Patients with Inflammatory Arthritis Treated with TNF-Inhibitors
Ana Maria Gheorghiu¹, Alexandru Garaiman², Alexandra Radu², Alina Soare³, Victoria Arama⁴, Dragos Bumbacea⁵, Rucsandra Dobrota⁶, Raida Oneata⁷, Simona Pintilie², Mihaela Milicescu⁷, Ioan Ancuta⁷, Andrei Martin², Mariana Sasu¹, Claudia Ciofu¹, Liviu Macovei¹, Victor Stoica⁷, Mihai Bojinca⁷ and Carina Mihai⁸, ¹Carol Davila University of Medicine and Pharmacy,Internal Medicine and Rheumatology Department ,,Dr.I.Cantacuzino'' Clinical Hospital, Bucharest, Romania, ²Internal Medicine and Rheumatology, CANTACUZINO HOSPITAL, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁴Infectious Diseases 1 Department, Matei Bals National Institute for Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁵Department of Pneumology, Elias Emergency University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁶Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ⁸Internal Medicine and Rheumatology Dept., Cantacuzino Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose: Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi). Objectives: To assess the incidence of active TB and the efficacy of…
Abstract Number: 1534 • 2017 ACR/ARHP Annual Meeting
Comparison of Long Term Anti-Tnf Survival in Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis; Data from Turkbio Registry
Gercek Can¹, Ediz Dalkılıc², Yavuz Pehlivan², Soner Senel³, Servet Akar⁴, Dilek Solmaz⁵, Suleyman Serdar Koca⁶, Nevsun İnanc⁷, Pamir Atagunduz⁷, Ayten Yazıcı⁸, Ayse Cefle⁸, Berna Goker⁹, Berrin Zengin¹, Sadettin Uslu¹⁰, Nurullah Akkoc¹¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Rheumatology, Uludag University Faculty of Medicine Rheumatology, bursa, Turkey, ³Rheumatology, Erciyes University Faculty of Medicine Rheumatology, kayseri, Turkey, ⁴Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁵Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, izmir, Turkey, ⁶Rheumatology, Fırat University Faculty of Medicine, elazıg, Turkey, ⁷Rheumatology, Marmara University Faculty of Medicine Rheumatology, istanbul, Turkey, ⁸Rheumatology, Kocaeli University Faculty of Medicine Rheumatology, kocaeli, Turkey, ⁹Rheumatology, Gazi Universty of Fakulty of Medicine, ankara, Turkey, ¹⁰Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ¹¹Rheumatology, Private Practice, Rheumatology, İzmir, Turkey
Background/Purpose: Limited data are available on anti-TNF survival in non-radiographic axial spondyloarthritis (nr-axSpA) patients and their long-term survival in ankylosing spondylitis (AS). The aim of…
Abstract Number: 2002 • 2017 ACR/ARHP Annual Meeting
Baseline 18F Sodium Fluoride Uptake of Vertebral Bodies but Not Vertebral Corners on Positron Emission Tomography Is Associated with Changes in Bone Mineral Density at Lumbar Vertebrae in Ankylosing Spondylitis: A 1-Year Longitudinal Study
Seung-Geun Lee¹, Keunyoung Kim², Seong-Min Kweon³, Eun-Kyoung Park⁴, Yun-Kyung Kim⁵ and Geun-Tae Kim⁶, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, Republic of (South), ²Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea, Republic of (South), ³Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, Busan, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, Republic of (South), ⁵Internal Medicine, Kosin University College of Medicine, Busan, South Korea, Busan, Korea, Republic of (South), ⁶Kosin University College of Medicine, Busan, Korea, Republic of (South)
Background/Purpose: 18F sodium fluoride (NaF) positron emission tomography (PET) allows quantitative assessment of osteoblastic bone synthesis in specific skeletal sites. Previous studies showed that increased…
Abstract Number: 2882 • 2017 ACR/ARHP Annual Meeting
IgG Galactosylation Status Combined with MYOM2 SNP Precisely Predicts Anti-TNF Response in Ankylosing Spondylitis
Jing Liu¹, Shifang Ren², Zhenmin Niu¹, Qi Zhu³, Wei Wan⁴, Jing Han², Yanyun Ma⁵, Weilin Pu⁶, Yuan Li¹, Xia Xu⁴, Yi Wang⁵, Dongbao Zhao⁴, Hui Zhang⁷, Feng Qian⁵, Xiaodong Zhou⁸, John D. Reveille⁹, Li Jin^1,10, Dong-yi He³, Hejian Zou^11,12, Jianxin Gu² and Jiucun Wang^10,12,13, ¹State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China, ²Department of Biochemistry and Molecular Biology, Key Laboratory of Glycoconjugate Research Ministry of Public Health, School of Basic Medical Sciences, Fudan University, Shanghai, China, ³Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Guanghua Integrative Medicine Hospital, Shanghai, China, ⁴Department of Rheumatology and Immunology, Changhai Hospital, Shanghai, China, ⁵Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China, ⁶State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences,, State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences and Institutes of Biomedical Sciences, Fudan University, Shanghai, China, Shanghai, China, ⁷School of Life Sciences, State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China, ⁸Internal Medicine-Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹University of Texas McGovern Medical School, Houston, TX, ¹⁰Fudan-Taizhou Institute of Health Sciences, Taizhou, China, ¹¹Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, ¹²Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China, ¹³State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, CN
Background/Purpose: Ankylosing spondylitis (AS) is an immune-mediated inflammatory disorder of spine and sacroiliac joints, which could lead to bony fusion of vertebral joints. TNF-blockers have…
Abstract Number: 1000 • 2017 ACR/ARHP Annual Meeting
Use of Mutual Information Theory in Development and Refinement of a Predictive Model for Early Identification of Ankylosing Spondylitis
Atul A. Deodhar¹, Cody Garges², Oodaye Shukla², Theresa Arndt², Tara Grabowsky² and Yujin Park³, ¹Oregon Health & Science University, Portland, OR, ²HVH Precision Analytics, LLC, King of Prussia, PA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Delayed diagnosis and treatment of ankylosing spondylitis (AS) contribute to the economic, physical and psychological burden on patients and their caregivers. The objective of…
Abstract Number: 1535 • 2017 ACR/ARHP Annual Meeting
Study of Potential Clinical and Biologic Predictors of Maintaining Good Response at 1 Year Follow-up, in Patients with Ankylosing Spondylitis Under Dose Reduction of TNFi Treatment
Mireia Moreno¹, Caridad Pontes², Ferran Torres³, Agusti Sellas-Fernandez⁴, Miriam Almirall⁵, Juan Carlos Torre-Alonso⁶, Teresa Clavaguera⁷, Carlos Rodriguez-Lozano⁸, Luis Francisco Linares⁹, Ana Urruticoechea-Arana¹⁰, Eduardo Collantes-Estevez¹¹, Rosa Morla¹², Delia Reina¹³, Eduardo Cuende¹⁴, Pedro Zarco¹⁵, Cruz Fernandez-Espartero¹⁶, Rosario García-Vicuña¹⁷, Jesus Sanz¹⁸, Xavier Juanola¹⁹, Antoni Vallano²⁰, Francisco J Blanco²¹, Raimon Sanmarti²², Gonzalo Calvo²³, Cristina Avendaño²⁴, Eugenio De Miguel²⁵, Roser Vives²⁶, Raul Veroz Gonzalez²⁷, Carlos Alberto Montilla-Morales²⁸ and Jordi Gratacos-Masmitja²⁹, ¹Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Spain, ²Clinic Pharmacology, Parc Tauli Hospital Universitari. I3PT. UAB, Sabadell, Spain, ³Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Valle Hebron, Barcelona, Spain, ⁵Rheumatology, Hospital del Mar, Barcelona, Spain, ⁶H Monte Naranco, Oviedo, Spain, ⁷Rheumatology. Palamós Hospital, Rheumatologist, Catalonia, Spain, ⁸Rheumatology, Hospital Universitario Dr. Negrin, Gran Canaria, Spain, ⁹Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ¹⁰Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ¹¹Rheumatology, IMIBIC-Hospital Universitario Reina Sofia, Cordoba, Spain, ¹²Rambla Vella, 14, Hospital La Tecla, Tarragona, Spain, ¹³Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ¹⁴University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ¹⁵H Fundación Alcorcón, Alcorcón, Spain, ¹⁶Rheumatology, Hospital de Mostoles, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁸Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁰Clinic pharmacology, Hospital Universitari Bellvitge, Barcelona, Spain, ²¹Servicio de Reumatología. Area Genomica. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ²²Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ²³Clinic pharmacology, Hospital Clinic Barcelona, Barcelona, Spain, ²⁴Clinic pharmacology, Hospital Puerta de Hierro, Madrid, Spain, ²⁵Medicine, Universidad Autonoma Madrid, MADRID, Spain, ²⁶Clinic pharmacology, Parc Tauli Hospital Universitari. I3PT. UAB, Sabadell, Spain, ²⁷Hospital de Mérida, Mérida, Spain, ²⁸Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²⁹Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Barcelona, Spain
Background/Purpose: Some clinical guidance recommends empirical TNFi dose reductions in AS patients despite lack of robust supportive evidence. Recently, we communicated that a strategy of…
Abstract Number: 2241 • 2017 ACR/ARHP Annual Meeting
Patterns and Outcomes on Disease Activity in Patients with Ankylosing Spondylitis (AS) Using Smart System of Disease Management (SSDM): Analysis of T2T Pattern Shift and Influential Factors
Jing Xue¹, Wenqiang Fan², Hua Wei³, Jing Yang⁴, Hui Song⁵, Hongbin Li⁶, Hongzhi Wang⁷, Xinwang Duan⁸, Zhenchun Zhang⁹, Jianlin Huang¹⁰, Yasong Li¹¹, Jian Ding¹², Xiaofei Shi¹³, Miaojia Zhang¹⁴, Zhenbiao Wu¹⁵, Cundong Mi¹⁶, Fei Xiao¹⁷, Hui Xiao¹⁷, Yuhua Jia¹⁷, Rui Bai¹⁷, Yan Bu¹⁷ and Huaxiang Wu¹⁸, ¹88 Jiefang Road, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ²Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ³No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁴Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ⁵Beijing Jishuitan Hospital, Beijing, China, ⁶The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China, ⁷The First Hospital of Jiaxing, Jiaxing, China, ⁸Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁹People's Hospital of Linyi, Shandong, Linyi, China, ¹⁰Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ¹¹Zhejiang Provincal People's Hospital, Hangzhou, China, ¹²Ningbo City Medical Treatment Center Lihuili Hospital, Ningbo, China, ¹³The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹⁴Department of Rheumatology and Immunology, Jiangsu Province Hospital, Nanjing, China, ¹⁵The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, China, ¹⁶The Second Affiliated Hospital of Guangxi Medical University, Nanning, China, ¹⁷Gothic Internet Technology Corporation, Shanghai, China, ¹⁸The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Background/Purpose: This study is to evaluate pattern shifts and outcome trends of treat-to-target (T2T) under standard of care in ankylosing spondylitis (AS) patients with interactive…
Abstract Number: 1001 • 2017 ACR/ARHP Annual Meeting
Persistence, Discontinuation, and Switching Patterns Among Ankylosing Spondylitis Patients Newly Initiating Biologic Therapy
Theresa Hunter¹, Krista Schroeder², Sarah Al Sawah² and David Sandoval Calderon², ¹Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: The primary goals of treating Ankylosing Spondylitis (AS) patients are to maximize long-term health-related quality of life through control of symptoms and inflammation, prevention…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].